Evidence map›Paper›PMID 35120764›Full record

ArticleTransplantation proceedings

COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies.

Julia Zimmermann, Olaf M Glueck, Jan M Fertmann, Wulf G Sienel, Gökce Yavuz, Fuad Damirov, Julia R Kovács, Amanda Tufman, Michael Irlbeck, Nikolaus Kneidinger and 4 more

Open access · greenAbstract read
In one paragraph

Article in Transplantation proceedings. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Julia ZimmermannDepartment of Thoracic Surgery University Hospital, LMU Munich, Munich, Germany. Electronic address: Julia.Zimmermann@med.uni-muenchen.de.
Olaf M GlueckDepartment of Thoracic Surgery University Hospital, LMU Munich, Munich, Germany.
Jan M FertmannDepartment of Thoracic Surgery University Hospital, LMU Munich, Munich, Germany.
Wulf G SienelDepartment of Thoracic Surgery University Hospital, LMU Munich, Munich, Germany.
Gökce YavuzDepartment of Thoracic Surgery University Hospital, LMU Munich, Munich, Germany.
Fuad DamirovDepartment of Thoracic Surgery University Hospital, LMU Munich, Munich, Germany.
Julia R KovácsDepartment of Thoracic Surgery University Hospital, LMU Munich, Munich, Germany.
Amanda TufmanDepartment of Medicine V, University Hospital, LMU Munich, Germany; Member of the German Center for Lung Research (DZL), Munich, Germany.
Michael IrlbeckDepartment of Anaesthesiology, University Hospital, LMU Munich, Munich, Germany.
Nikolaus KneidingerDepartment of Medicine V, University Hospital, LMU Munich, Germany; Member of the German Center for Lung Research (DZL), Munich, Germany.
Sebastian MichelDepartment of Cardiac Surgery, University Hospital, LMU Munich, Munich, Germany; Member of the German Center for Lung Research (DZL), Munich, Germany.
Teresa KaukeDepartment of Thoracic Surgery University Hospital, LMU Munich, Munich, Germany.
Rudolf A HatzDepartment of Thoracic Surgery University Hospital, LMU Munich, Munich, Germany; Member of the German Center for Lung Research (DZL), Munich, Germany.
Christian P SchneiderDepartment of Thoracic Surgery University Hospital, LMU Munich, Munich, Germany; Member of the German Center for Lung Research (DZL), Munich, Germany.
LMU Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 causes a wide range of symptoms, with particularly high risk of severe respiratory failure and death in patients with predisposing risk factors such as advanced age or obesity. Recipients of solid organ transplants, and in particular lung transplantation, are more susceptible to viral infection owing to immune suppressive medication. As little is known about the SARS-CoV-2 infection in these patients, this study was undertaken to describe outcomes and potential management strategies in early COVID-19 infection early after lung transplantation.

methodsWe describe the incidence and outcome of COVID-19 in a cohort of recent lung transplant recipients in Munich. Six of 186 patients who underwent lung transplantation in the period between March 2019 and March 2021 developed COVID-19 within the first year after transplantation. We documented the clinical course and laboratory changes for all patients showing differences in the severity of the infection with COVID-19 and their outcomes.

resultsThree of 6 SARS-CoV-2 infections were hospital-acquired and the patients were still in inpatient treatment after lung transplantation. All patients suffered from symptoms. One patient did not receive antiviral therapy. Remdesivir was prescribed in 4 patients and the remaining patient received remdesivir, bamlanivimab and convalescent plasma.

conclusionsCOVID-19 does not appear to cause milder disease in lung transplant recipients compared with the general population. Immunosuppression is potentially responsible for the delayed formation of antibodies and their premature loss. Several comorbidities and a general poor preoperative condition showed an extended hospital stay.

Indexed as

COVID-19Antibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntiviral AgentsCOVID-19 SerotherapyHumansImmunization, PassiveLungSARS-CoV-2Transplant RecipientsAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingAntiviral Agentsbamlanivimab

Identifiers

PMID35120764
PMCPMC8743506
OpenAlexW4206568825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.